Pharmaceutique, Sciences de la vie, Technologies disponibles

C75: Une nouvelle façon de bloquer la division des cellules cancéreuses

C75 bloque spécifiquement la division des cellules cancéreuses pour induire leur mort

-Description en anglais seulement-

Lung & colorectal (CRC) market opportunity

  • Highest cancer incidence (lung=1st and CRC=3rd)
  • The 2 biggest killer cancers
  • Lung cancer has the lowest 5-years survival rate (1.7/10)
  • 2023 global market (lung=$24.7B and CRC=$17.1B)
  • Highest global cancer therapeutics market share in 2017 (lung=13% and CRC=9.7%)
  • Great unmet need to provide more effective, less toxic and less expensive therapeutic strategies for cancer

Specific targeting of cancer cell division

  • In contrast to normal cells, most tumor cells contain multiple centrosomes. They can divide successfully because they can cluster these centrosomes into 2 spindle poles
  • A new mechanism of action: C75 targets the centrosome clustering by disrupting the integrity of the mitotic pole
  • C75 selectively reduces cancer cell viability
  • Pre-clinical development stage: in-vitro proof of concept completed in colorectal and lung cancer models
  • A technology developed by Dr. Alisa Piekny and Dr. Pat Forgione at Concordia University

A promising drug for most cancers

  • C75 is a small molecule derived from thienoisoquinoline
  • Easy to produce and non-toxic so far
  • C75 could be used alone or in combination therapy with other anti-cancer agents
  • Potential treatment for multiple cancer types including CRC, lung and breast cancers


Patents: PCT/CA2017/051473 & PCT/CA2017/051454

Business opportunity for partnering on pre-clinical development or in-licensing


If you are interested by this technology, please contact :

Catherine Gagnon, VP Business Development, (514) 924-9003


Concordia University


Photo Dr. Alisa Piekny

Dr. Alisa Piekny, Associate Professor, Department of Biology


Dr. Piekny is an Associate Professor in Biology at Concordia University. She co-directs the Centre for Microscopy and Cellular Imaging, and has extensive expertise in cell biology. She did her PhD in Biochemistry and Molecular Biology at the University of Calgary, and her PDF at the Institute of Molecular Pathology in Vienna, Austria and at the University of Chicago, USA. Her research studies the mechanisms regulating cell division and migration, and is interested in how these mechanisms are hijacked by cancers. Her lab receives external funding from NSERC, FRQ-NT and NIH. She collaborates with researchers in Engineering and Chemistry to develop diagnostic and delivery tools for cancers, and her collaboration with Dr. Forgione is developing new anti-cancer drugs. ​

Photo Dr. Pat Forgione

Dr. Pat Forgione, Associate professor, Department of Chemistry and Biochemistry

Dr. Pat Forgione is an Associate Professor in the Department of Chemistry and Biochemistry at Concordia University. His research interests lie in the area of organic method development, green and medicinal chemistry. His previous experience as a research scientist at Boehringer Ingelheim Canada, Ltd culminated in his co-invention of Faldaprevir, an orally absorbed drug with demonstrated anti-HCV activity in infected humans. Additionally, he is the co-inventor on numerous patents in the area of HCV and cancer drug-discovery involving (in collaboration with Dr. Alisa Piekny) the design, synthesis and biological/pharmacological evaluation of inhibitors. Overall, he has published over 35 research papers, contributed eight invited book chapters and reviews and supervised over 60 research scientists, graduate and undergraduate research projects. His research experience provides a unique hybrid of industrial and academic medicinal chemistry knowledge that is directed towards new directions in drug discovery.